New Insights into Adjuvant Therapy in Renal Cell Carcinoma: Is the Chapter of VEGF Inhibitors Definitely Closed?

Florent Peyraud; Mathieu Larroquette; Alain Ravaud; Marine Gross-Goupil

doi:10.1016/j.eururo.2021.03.011

New Insights into Adjuvant Therapy in Renal Cell Carcinoma: Is the Chapter of VEGF Inhibitors Definitely Closed?

Eur Urol. 2021 Sep;80(3):269-274. doi: 10.1016/j.eururo.2021.03.011. Epub 2021 Mar 31.

Authors

Florent Peyraud¹, Mathieu Larroquette¹, Alain Ravaud², Marine Gross-Goupil³

Affiliations

¹ Department of Medical Oncology, Bordeaux University Hospital, Bordeaux, France.
² Department of Medical Oncology, Bordeaux University Hospital, Bordeaux, France; Bordeaux University, Bordeaux, France.
³ Department of Medical Oncology, Bordeaux University Hospital, Bordeaux, France. Electronic address: marine.gross-goupil@chu-bordeaux.fr.

PMID: 33810923
DOI: 10.1016/j.eururo.2021.03.011

Abstract

Adjuvant therapy with antiangiogenic agents in locoregional renal cell carcinoma did not translate into a sufficient benefit and highlight the crucial role of patient selection. Ongoing clinical trials with immune-targeted agents hold great promise for this unmet clinical need.

Publication types

Editorial

MeSH terms

Angiogenesis Inhibitors* / adverse effects
Angiogenesis Inhibitors* / therapeutic use
Carcinoma, Renal Cell* / drug therapy
Chemotherapy, Adjuvant / adverse effects
Chemotherapy, Adjuvant / methods*
Clinical Trials as Topic
Combined Modality Therapy
Humans
Immune Checkpoint Inhibitors / therapeutic use
Kidney Neoplasms* / drug therapy
Research Design
Treatment Failure
Vascular Endothelial Growth Factor A / antagonists & inhibitors

Substances

Angiogenesis Inhibitors
Immune Checkpoint Inhibitors
Vascular Endothelial Growth Factor A